Kiadis Pharma Announces Successful Completion Of Rhitol(TM) Phase II Clinical Study

Oncology focused biopharmaceutical product development company Kiadis Pharma announced that it has successfully finalized its Rhitol(TM) Phase II clinical trial with the last patient completing its six month treatment cycle. Rhitol(TM) is evaluated as treatment for patients with extensive chronic Graft versus Host Disease (GvHD) intolerant or resistant to standard immunosuppressive treatment.

More: continued here

Filed under: Immune System / Vaccines on February 7th, 2008